biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) DAC HYP A daclizumab high-yield process Multiple sclerosis Phase IIb data showed it reduced the annualized relapsed rate by 54%, meeting the study's primary endpoint 4/5/13 Fibrocell Science Inc. (Exton, Pa.) LaViv Autologous fibroblast injection azficel-T Moderate-to-severe acne scars Phase II study demonstrated that azficel-T treatment was associated with clinically meaningful improvement

biotech company stock symbols can be found in the stock report located on the last two pages of this issue

the primary endpoint was met in arm C with a complete early viral response of 64%, compared to 30% in the control arm 4/30/13 Vertex Pharmaceuticals Inc. (Cambridge, Mass.) ALS-2200 VX-135 Hepatitis C virus genotypes 1, 3 or 4 Data from a viral kinetic study showed a reduction in HCV RNA after seven days of dosing 4/24/13 Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

biotech company stock symbols can be found in the stock report located on the last two pages of this issue

biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Success came when the team reached out to biotech company SomaLogic, whose aptamer technology was able to identify GDF-11 as the protein responsible for the effects seen in the parabiosis experiments

Mohan said Huahai, of Linhai, China, is moving into biologics, and had been looking to partner with a small biotech company, and that for Oncobiologics, partnering with a midsized generics company would "really help us launch our biosimilars" as well as providing financial support for the company

BIO criticized India, China, Brazil and Canada, among others, for failing to provide adequate IP protection for biotech companies and voiced support for the USTR's efforts to encourage stronger IP policies throughout the world

We bring pharma companies in from around the world for a couple of days, and we provide the opportunity for them to have one-on-one meetings with our companies and for our companies to make presentations to them to encourage more partnership between the funding arms of those pharma companies our biotech companies here," Panetta said

AbbVie took several dozen marketed products and a portfolio of late-stage compounds in immunology, neuroscience and oncology, leaving Abbott to focus on diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. (See BioWorld Today, Jan. 3, 2013.) In April Canadian biotech company Resverlogix Corp., of Calgary, Alberta, said it was spinning out its epigenetics platform into RVX Therapeutics Inc., leaving ApoA-I stimulating drug candidate, RVX-208, with the parent company

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date FEBRUARY Exelixis Inc. (South San Francisco) Swedish Orphan Biovitrum AB (Stockholm, Sweden) ND Partnership to distribute and commercialize Cometriq (cabozantinib) for metastatic medullary thyroid cancer in the European Union and potentially other countries The agreement will last for three years, with Exelixis maintaining full commercial rights outside the covered territory and for all other indications 2/25

Company Company Deal Value Biogen Idec Inc. Elan Corp. plc $3.25B MacroGenics Inc. Gilead Sciences Inc. $1B bluebird bio Celgene Corp. $225M The Medicines Co. Alnylam Pharmaceuticals Inc. $205M Afraxis Inc. Genentech Inc. $187.5M BIND Biosciences Inc. Amgen Inc. $180.5M Concert Pharmaceuticals Inc. Jazz Pharmaceuticals plc $120M Genentech Inc. RQx Pharmaceuticals Inc. $111M

Ltd. (Sydney, Australia) ND Agreement to commercialize a family of anti-inflammatory Phylomer peptides for pharmaceutical use Bio-Link will work with Phylogica to monetize those assets through out-licensing or disposal of the Phylomer peptides to a pharma or biotech company 2/6/13 Santen Inc. (Emeryville, Calif.; subsidiary of Santen Pharmaceuticals Co. Ltd.) Clearside Biomedical Inc. (Alpharetta, Ga.) $7.9 Research collaboration for posterior ocular diseases Santen will join other investors to

As a consequence they did not feature prominently on the product development radar screens of either pharma or biotech companies

As a consequence, they did not feature prominently on the product development radar screens of pharma or biotech companies

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Cevec Pharmaceuticals GmbH (Cologne, Germany) Yuhan Corp. (Seoul, South Korea) ND CAP-Technology licensing deal enabling Yuhan to use Cevec's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins Financial terms were not disclosed 12/21/12 GlaxoSmithKline plc (London) The University of Texas MD Anderson Cancer Center (Houston) $335 Research